Mentoring and patient-oriented research in antimicrobial resistance

抗菌素耐药性的指导和以患者为导向的研究

• 批准号: 7571802
• 负责人: EBBING LAUTENBACH
• 金额: $ 17.84万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-02-15 至 2014-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7571802
• 关键词: Antibiotic Resistance; Antibiotics; Antimicrobial Resistance; Biometry; Clinical; Clinical Investigator; Clinical Research; Clinical and Translational Science Awards; Cohort Studies; Commit; Communicable Diseases; Development; Environment; Epidemiology; Escherichia coli; Escherichia coli Infections; Evolution; Funding; Gastrointestinal tract structure; Grant; Human; Individual; Instruction; Intervention; Laboratories; Long-Term Care; Master of Science; Medicine; Mentors; Mid-Career Clinical Scientist Award (K24); Organism; Pathway interactions; Patients; Peer Review; Pennsylvania; Play; Principal Investigator; Research; Research Infrastructure; Research Personnel; Research Training; Resistance; Role; Study models; Time; Training; Training Programs; Universities; Virulence Factors; clinical epidemiology; cohort; data management; driving force; fluoroquinolone resistance; innovation; medical schools; next generation; patient oriented; patient oriented research; professor; programs; prospective

DESCRIPTION (provided by applicant): The applicant is an Associate Professor of Medicine in the Division of Infectious Diseases, an Associate Professor of Epidemiology in the Department of Biostatistics and Epidemiology, and a Senior Scholar at the Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania School of Medicine. He is an established clinical investigator with an extensive track record as the Principal Investigator of peer- reviewed federal funding. The candidate has developed a highly successful and innovative patient-oriented research program focusing on the epidemiology of antimicrobial resistance. He also has a clear record of accomplishment and commitment to mentoring the next generation of patient-oriented researchers. He has played a critical role in building clinical research training opportunities through expansion of research training programs, course development and instruction, and individual mentoring. The University of Pennsylvania is committed to providing the applicant with a strong environment for patient-oriented research and mentoring, including multiple institutional training grants, an institutional Clinical and Translational Science Award (CTSA) program, an extraordinarily successful Master of Science in Clinical Epidemiology (MSCE) training program, and outstanding laboratory, biostatistics, and data management support. One of the applicant's current R01s is a prospective cohort study examining the epidemiology of gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli (FQREC) in long-term care facility (LTCF) residents. While this study focuses on several critical steps in the ultimate development of clinical FQREC infection, the earliest aspects of this pathway of colonization (i.e., the progression of an E. constrain from FQ-susceptible to FQ-resistant) remain unstudied. Elucidation of these earlier steps in the evolution of FQ resistance is critical in identifying key patient variables (e.g., antibiotic use) and organism variables (e.g., virulence factors) which may be amenable to intervention. Indeed, this application represents a powerful human model for studying evolution of antibiotic resistance in the clinical setting. With its established infrastructure and unique longitudinal patient cohort, the ongoing LTCF R01 study provides a distinctive opportunity to answer the important new questions proposed in this application. Furthermore, the new proposed research will expand considerably the scope of the ongoing LTCF R01. This unique research infrastructure will also offer valuable research and mentoring opportunities for the applicant's trainees. Support from the K24 will allow the candidate to substantially expand his research program and considerable track record of successful individual mentoring in patient-oriented research focused on antimicrobial resistance. RELEVANCE (See instructions): Dramatic increases in antimicrobial resistance threaten our most commonly used antibiotics. The research proposed in this application will advance our understanding of the forces driving resistance, thereby identifying strategies to curb further emergence of resistance. Support from a K24 award will provide Dr. Lautenbach with sufficient time to expand his research program and build on his considerable track record of successful mentoring in patient-oriented research focused on antimicrobial resistance.

描述（由申请人提供）：申请人是传染病科医学副教授，生物统计学和流行病学系流行病学副教授，以及宾夕法尼亚大学医学院临床流行病学和生物统计学中心的高级学者。他是一位既定的临床研究者，拥有广泛的往绩记录，是同行审查的联邦资金的主要研究者。该候选人开发了一项非常成功和创新的以患者为导向的研究计划，重点介绍了抗菌素耐药性的流行病学。他还清楚地记录了指导下一代患者研究人员的成就和承诺。通过扩展研究培训计划，课程发展和教学以及个人指导，他在建立临床研究培训机会方面发挥了关键作用。宾夕法尼亚大学致力于为申请人提供针对患者的研究和指导的强大环境，包括多个机构培训补助金，机构临床和转化科学奖（CTSA）计划，这是一个非常成功的临床科学硕士学位，领域的临床流行病学培训计划（MSCE）培训计划，以及杰出的实验室，生物学，生物，生物，以及数据管理和数据管理。申请人当前的R01是一项前瞻性队列研究，研究了长期护理设施（LTCF）居民中耐氟喹诺酮类药物（FQREC）的胃肠道定植的流行病学。尽管这项研究侧重于临床FQREC感染的最终发展的几个关键步骤，但这种定殖途径的最早方面（即，E. E.限制了FQ敏感到耐FQ耐FQ的限制）仍然没有研究。阐明FQ耐药性演变的这些早期步骤对于鉴定关键的患者变量（例如抗生素使用）和生物变量（例如，毒力因子）至关重要，这可能是可易于干预的。实际上，该应用代表了在临床环境中研究抗生素耐药性进化的强大人类模型。凭借其既定的基础设施和独特的纵向患者队列，正在进行的LTCF R01研究为回答本应用程序中提出的重要新问题提供了独特的机会。此外，新提出的研究将大大扩大正在进行的LTCF R01的范围。这种独特的研究基础设施还将为申请人的受训者提供宝贵的研究和指导机会。 K24的支持将使候选人可以大大扩展其研究计划，并在以抗菌素耐药为方面的患者研究中成功进行个人指导的成功记录。相关性（请参阅说明）：抗菌耐药性的急剧增加威胁着我们最常用的抗生素。在本应用程序中提出的研究将促进我们对驱动抵抗力的力量的理解，从而确定抑制抵抗力进一步出现的策略。 K24奖的支持将为Lautenbach博士提供足够的时间扩展其研究计划，并以他在以抗菌抗性为例的以患者为导向的研究中成功指导的相当多记录。